|Dr. Bassil I. Dahiyat Ph.D.||Co-Founder, Chief Exec. Officer, Pres and Director||761.61k||5.14M||1970|
|Mr. John J. Kuch||VP of Fin. & Sec.||434.18k||984.34k||1959|
|Dr. John R. Desjarlais Ph.D.||Chief Scientific Officer and Sr. VP of Research||491.68k||3.47M||1964|
|Dr. Edgardo Baracchini Jr., Ph.D., M.B.A.||Chief Bus. Officer||394.46k||591.76k||1959|
|Dr. Paul A. Foster M.D., F.A.H.A.||Chief Medical Officer and Sr. VP||602.33k||84.55k||1954|
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug, that in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; and AMG424, a bispecific CD38 x CD3 preclinical candidate for various myeloma. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104, which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. to develop and commercialize bispecific and other Fc engineered antibody drug candidates using its proprietary XmAb technologies and drug candidates, as well as MorphoSys Ag to develop and commercialize bispecific antibody product candidates; license agreement with Amgen Inc. to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc.was founded in 1997 and is headquartered in Monrovia, California.
Xencor, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 4; Compensation: 9.